SKYRIZI (risankizumab) is an interleukin-23 antagonist used to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults.

Enthesitis and dactylitis are common symptoms of PsA, affecting approximately 35-50% and 40% of patients, respectively. Individuals with enthesitis tend to experience higher disease activity, erosive damage, and lower quality of life compared to those without enthesitis. Likewise, dactylitis is linked to increased disease activity, reduced physical function, erosive disease, and a lower chance of reaching minimal disease activity.

In the combined analysis of patients from the KEEPsAKE 1 and 2 trials, 892 individuals (444 treated with risankizumab and 448 with placebo) had enthesitis at the beginning. In contrast, 392 patients (188 on risankizumab and 204 on placebo) had dactylitis. Across all evaluated sites, treatment with risankizumab led to a higher rate of resolving enthesitis and dactylitis by Week 24 compared to placebo. The proportion of patients achieving resolution with risankizumab remained consistent across all sites studied. Additionally, patients who switched from placebo to risankizumab 150 mg at Week 24 achieved similar resolution rates as those continuously on risankizumab by Week 52. Analyzing resolution rates based on baseline severity showed consistent responses in patients with milder disease at all-time points. Patients with more severe disease at the start experienced ongoing improvement in resolving enthesitis and dactylitis with risankizumab treatment from Week 24 to 52, with this resolution maintained up to Week 100.

Conclusion: Psoriatic arthritis affects around 30% of individuals with psoriasis at some time in their lives. IL-23 Inhibitors are effective treatments for patients with Psoriatic Arthritis. In 2022, the FDA approved risankizumab for treating PsA. This retrospective analysis demonstrates that risankizumab 150 mg effectively resolves enthesitis and dactylitis across all evaluated sites and various baseline severity levels. Risankizumab's main competitor is guselkumab, which generated USD 3.1 billion in sales in 2023, compared to risankizumab USD 2.3 billion in total sales for the same year.